Loading people...
Andrew Kleiboeker is an Associate at RiverVest Venture Partners in Saint Louis, Missouri, where he specializes in evaluating early-stage biopharmaceutical and medical device investments. He originally joined the healthcare venture capital firm as an Analyst in June 2020, subsequently advancing to Senior Analyst in December 2022 before assuming his current position in July 2024. In this capacity, he evaluates new early-stage life sciences opportunities through rigorous due diligence while conducting complex financial analysis for portfolio company financings and mergers and acquisitions. Kleiboeker currently holds a board observer seat at InterVene Medical, a clinical-stage medical device enterprise within the RiverVest portfolio. He earned a Bachelor of Science in Business Administration summa cum laude from Washington University in Saint Louis, where he also played varsity baseball, joined Beta Gamma Sigma, and received the Powell Niland Prize.
Andrew Kleiboeker is a key Analyst at RiverVest, a distinguished venture capital firm renowned for its strategic investments in the life science sector. In his capacity as an Analyst, Andrew plays a crucial role in the firm's investment process, contributing significantly to the identification, evaluation, and execution of new opportunities. His work is fundamental to RiverVest's mission of funding innovative companies that are developing groundbreaking solutions in healthcare.
At RiverVest, Andrew Kleiboeker's primary focus areas align with the firm's specialization in early-stage and growth-stage life science companies. This includes a deep dive into biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health innovations. He is actively involved in market research, competitive analysis, and financial modeling, providing critical insights that inform investment decisions. Andrew's analytical rigor helps the RiverVest team assess the scientific merit, market potential, and commercial viability of prospective portfolio companies.
Andrew's career background reflects a strong foundation in both scientific understanding and financial analysis, essential for navigating the complex landscape of life science venture capital. Professionals in his role typically possess a blend of scientific acumen, often with advanced degrees in relevant fields, combined with experience in finance, consulting, or the healthcare industry. This multidisciplinary expertise allows Andrew Kleiboeker to effectively evaluate the technical intricacies of new technologies while also understanding their broader market implications and financial projections. His contributions are vital in supporting RiverVest's partners and principals through the rigorous due diligence process, ensuring that the firm invests in companies poised for significant impact and returns.
While specific notable investments for Andrew Kleiboeker are part of the collaborative effort at RiverVest, his work directly supports the firm's overall success in backing transformative life science ventures. He assists in monitoring portfolio company performance, identifying potential challenges, and contributing to strategic initiatives that help these companies achieve their milestones. Andrew's dedication to uncovering and nurturing promising innovations reinforces RiverVest's position as a leader in the life science investment community, ultimately helping to bring new therapies and technologies to patients worldwide.
Andrew Kleiboeker is an Analyst at RiverVest, a leading venture capital firm specializing in life science investments. He supports the firm's investment process, from deal sourcing to portfolio management.
As an Analyst at RiverVest, Andrew Kleiboeker supports investments in a wide range of life science sectors, including biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health innovations.
Andrew Kleiboeker works as an Analyst at RiverVest, a prominent venture capital firm focused on the life science industry.
